Galectin Therapeutics (NASDAQ:GALT) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why

Posted by Francis Steltz on Oct 17th, 2026

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report)’s share price crossed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $3.29 and traded as high as $3.84. Galectin Therapeutics shares last traded at $3.71, with a volume of 119,182 shares traded.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Monday, September 14th. Zacks Research upgraded shares of Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $11.00.

Get Our Latest Research Report on GALT

Galectin Therapeutics Stock Performance

The company has a market capitalization of $238.41 million, a price-to-earnings ratio of -8.42 and a beta of 0.38. The business has a 50 day moving average price of $3.84 and a 200-day moving average price of $3.29.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.05). As a group, equities analysts predict that Galectin Therapeutics Inc. will post -0.30 EPS for the current fiscal year.

Hedge Funds Weigh In On Galectin Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Hopwood Nicholas Hunter acquired a new stake in shares of Galectin Therapeutics during the 2nd quarter worth approximately $322,000. Archer Investment Corp bought a new stake in shares of Galectin Therapeutics in the 2nd quarter valued at $81,000. Argyle Capital Partners LLC bought a new position in Galectin Therapeutics during the second quarter worth $62,000. Bank of New York Mellon Corp acquired a new stake in Galectin Therapeutics in the second quarter worth $491,000. Finally, Bank of America Corp DE grew its holdings in Galectin Therapeutics by 114.9% in the first quarter. Bank of America Corp DE now owns 53,862 shares of the company’s stock worth $150,000 after purchasing an additional 28,799 shares during the period. 11.68% of the stock is currently owned by institutional investors.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics Inc (NASDAQ:GALT) is a biotechnology company focused on developing therapies that target galectin-3, a protein believed to play a role in fibrosis, inflammation and cancer biology. The company’s research is aimed at addressing serious chronic diseases for which treatment options remain limited.

Galectin Therapeutics’ lead investigational product is belapectin, also known as GR-MD-02. The drug is designed to inhibit galectin-3 and has been studied primarily in patients with advanced liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and portal hypertension.